The sleeve gastrectomy is the most common bariatric procedure, involving the removal of 80% of the stomach to create a narrow gastric tube that restricts food intake and reduces hunger hormones (ghrelin). This typically results in a 25–35% total body weight loss (approximately 50–70% excess weight loss), along with excellent resolution of comorbidities.

Advantages of sleeve gastrectomy over gastric bypass include its simplicity and safety, with fewer long-term complications such as dumping syndrome, ulcers, bowel obstructions, and vitamin deficiencies.

The Roux-en-Y Gastric Bypass (RYGB) is a well-established bariatric procedure that creates a small stomach pouch and reroutes the small intestine, significantly reducing food intake and calorie absorption. This typically results in a 25–35% total body weight loss (approximately 50–70% excess weight loss).

It provides marked improvement in obesity-related comorbidities, specifically Type 2 Diabetes, PCOS and Sleep apnoea.

The Single Anastomosis/Mini Gastric Bypass (MGB) is a simplified version of the RYGB, involving the creation of a long, narrow stomach pouch and a single connection to a loop of the small intestine.

This reduces food intake and calorie absorption, leading to similar weight loss (approximately 25–35% total body weight loss) and metabolic outcomes as RYGB.

SADI-S is probably the most powerful weight loss procedure suitable for both primary and revisionary cases following sleeve gastrectomy, typically achieving the highest excess weight loss (around 80–90% EWL).

It consists of a sleeve gastrectomy followed by a small bowel bypass, connecting the duodenum to the ileum to reduce absorption and alter metabolic hormones.

Intestinal Bipartition (IB) is a relatively new type of bariatric surgery that involves dividing the small intestine into two separate pathways. One pathway is much shorter than the other. Food is routed through both pathways, but the shorter pathway allows for less absorption of nutrients and calories.

This procedure shows strong promise for people with type 2 diabetes who are obese or overweight.